

Technology Available for Industry-Academia Collaboration or Technology Licensing.  
“A Potential COVID-19 Therapeutic Compound”

Date: 2020.4.16

1. Title:  
NHRI technology, “A Potential COVID-19 Therapeutic Compound” (abbreviated as “**The Technology**”) available for industry-academia collaboration or technology licensing.
2. Description:  
The Technology is a novel compound which, in coronaviral infected cells, targets the RNP complex containing viral RNA and nucleoprotein to block viral replication and activities for anti-coronaviral mechanism. Besides, it displayed potent *in vitro* activities for a wide spectrum of carcinoma cell lines as well as demonstrated both *in vitro* and *in vivo* activities against cancers, inflammatory diseases and coronaviruses.
3. Potential collaboration partner qualifications:
  - (1) be incorporated and approved by law and does not have any record of misconduct or conviction for any offense
  - (2) better to have related experience and skills for developing **The Technology**
  - (3) better to have experience of international collaboration and clinical trial
  - (4) better to be ready to invest or be able to raise the funds
4. Registration :  
Please contact to Mr. Hua-Hsuan Liang or Ms. Wen-Chuan Hsieh (Address: Technology Transfer and Incubation Center, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 35053, Taiwan, R.O.C., Tel: +88637-246166#33206/33209, E-mail: [huahsuan@nhri.org.tw](mailto:huahsuan@nhri.org.tw); [wenchuan@nhri.org.tw](mailto:wenchuan@nhri.org.tw) ).
5. Other:
  - (1) If **The Technology** has been exclusively licensed, this announcement will automatically invalid.
  - (2) NHRI retains the right to modify and terminate this announcement.
  - (3) For detailed status of **The Technology**, please contact to the case officer.

Attachments:

I: Announcement

II: Technology Transfer Vendor Qualification Form

III: Industry-Academia Collaboration Proposal